Profound functional suppression of tumor-infiltrating T-cells in ovarian cancer patients can be reversed using PD-1-blocking antibodies or DARPin proteins

PD-1/PD-L1 blockade has revolutionized the field of immunooncology. Despite the relative success, the response rate to anti-PD-1 therapy requires further improvements. Our aim was to explore the enhancement of T-cell function by using novel PD-1-blocking proteins and compare with clinically approved...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Foord, Emelie (VerfasserIn) , Klynning, Charlotte (VerfasserIn) , Schoutrop, Esther (VerfasserIn) , Derani, Judith (VerfasserIn) , Krieg, Jennifer (VerfasserIn) , Mörtberg, Anette (VerfasserIn) , Müller, Mischa R. (VerfasserIn) , Herzog, Christel (VerfasserIn) , Schiegg, Dieter (VerfasserIn) , Villemagne, Denis (VerfasserIn) , Fiedler, Ulrike (VerfasserIn) , Snell, Dan (VerfasserIn) , Kebble, Benjamin (VerfasserIn) , Mattsson, Jonas (VerfasserIn) , Levitsky, Victor (VerfasserIn) , Uhlin, Michael (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: 4 August 2020
In: Journal of immunology research

ISSN:2314-7156
DOI:10.1155/2020/7375947
Online-Zugang:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1155/2020/7375947
Verlag, lizenzpflichtig, Volltext: https://www.hindawi.com/journals/jir/2020/7375947/
Volltext
Verfasserangaben:Emelie Foord, Charlotte Klynning, Esther Schoutrop, Judith M. Förster, Jennifer Krieg, Anette Mörtberg, Mischa R. Müller, Christel Herzog, Dieter Schiegg, Denis Villemagne, Ulrike Fiedler, Dan Snell, Benjamin Kebble, Jonas Mattsson, Victor Levitsky, and Michael Uhlin

MARC

LEADER 00000caa a2200000 c 4500
001 1733889515
003 DE-627
005 20220818211512.0
007 cr uuu---uuuuu
008 200929s2020 xx |||||o 00| ||eng c
024 7 |a 10.1155/2020/7375947  |2 doi 
035 |a (DE-627)1733889515 
035 |a (DE-599)KXP1733889515 
035 |a (OCoLC)1341361771 
040 |a DE-627  |b ger  |c DE-627  |e rda 
041 |a eng 
084 |a 33  |2 sdnb 
100 1 |a Foord, Emelie  |e VerfasserIn  |0 (DE-588)1218541784  |0 (DE-627)1733889965  |4 aut 
245 1 0 |a Profound functional suppression of tumor-infiltrating T-cells in ovarian cancer patients can be reversed using PD-1-blocking antibodies or DARPin proteins  |c Emelie Foord, Charlotte Klynning, Esther Schoutrop, Judith M. Förster, Jennifer Krieg, Anette Mörtberg, Mischa R. Müller, Christel Herzog, Dieter Schiegg, Denis Villemagne, Ulrike Fiedler, Dan Snell, Benjamin Kebble, Jonas Mattsson, Victor Levitsky, and Michael Uhlin 
264 1 |c 4 August 2020 
300 |b Illustrationen 
300 |a 12 
336 |a Text  |b txt  |2 rdacontent 
337 |a Computermedien  |b c  |2 rdamedia 
338 |a Online-Ressource  |b cr  |2 rdacarrier 
500 |a Gesehen am 29.09.2020 
520 |a PD-1/PD-L1 blockade has revolutionized the field of immunooncology. Despite the relative success, the response rate to anti-PD-1 therapy requires further improvements. Our aim was to explore the enhancement of T-cell function by using novel PD-1-blocking proteins and compare with clinically approved monoclonal antibodies (mAbs). We isolated T-cells from the ascites and tumor of 17 patients with advanced epithelial ovarian cancer (EOC) and analyzed the effects using the mAbs nivolumab and pembrolizumab and two novel engineered ankyrin repeat proteins (DARPin® proteins). PD-1 blockade with either mAb or DARPin® molecule significantly increased the release of IFN-γ, granzyme B, IL-2, and TNF-α, demonstrating successful reinvigoration. The monovalent DARPin® protein was less effective compared to its bivalent equivalent, demonstrating that bivalency brings an additional benefit to PD-1 blockade. Overall, we found a higher fold increase of lymphokine secretion in response to the PD-1 blockade by tumor-derived T-cells; however, the absolute amounts were significantly lower compared to the release from ascites-derived T-cells. Our results demonstrate that PD-1 blockade can only partially reinvigorate functionally suppressed T-cells from EOC patients. This warrants further investigation preferably in combination with other therapeutics. The study provides an early pilot proof-of-concept for the potential use of DARPin® proteins as eligible alternative scaffold proteins to block PD-1. 
700 1 |a Klynning, Charlotte  |e VerfasserIn  |4 aut 
700 1 |a Schoutrop, Esther  |e VerfasserIn  |4 aut 
700 1 |a Derani, Judith  |d 1991-  |e VerfasserIn  |0 (DE-588)1057039187  |0 (DE-627)795124171  |0 (DE-576)413087670  |4 aut 
700 1 |a Krieg, Jennifer  |e VerfasserIn  |4 aut 
700 1 |a Mörtberg, Anette  |e VerfasserIn  |4 aut 
700 1 |a Müller, Mischa R.  |e VerfasserIn  |4 aut 
700 1 |a Herzog, Christel  |e VerfasserIn  |4 aut 
700 1 |a Schiegg, Dieter  |e VerfasserIn  |4 aut 
700 1 |a Villemagne, Denis  |e VerfasserIn  |4 aut 
700 1 |a Fiedler, Ulrike  |e VerfasserIn  |4 aut 
700 1 |a Snell, Dan  |e VerfasserIn  |4 aut 
700 1 |a Kebble, Benjamin  |e VerfasserIn  |4 aut 
700 1 |a Mattsson, Jonas  |e VerfasserIn  |4 aut 
700 1 |a Levitsky, Victor  |e VerfasserIn  |4 aut 
700 1 |a Uhlin, Michael  |e VerfasserIn  |4 aut 
773 0 8 |i Enthalten in  |t Journal of immunology research  |d [Hoboken, NJ] : Wiley, 2014  |g (2020) Artikel-Nummer 7375947, 12 Seiten  |h Online-Ressource  |w (DE-627)821910469  |w (DE-600)2817541-4  |w (DE-576)429186746  |x 2314-7156  |7 nnas  |a Profound functional suppression of tumor-infiltrating T-cells in ovarian cancer patients can be reversed using PD-1-blocking antibodies or DARPin proteins 
773 1 8 |g year:2020  |g extent:12  |a Profound functional suppression of tumor-infiltrating T-cells in ovarian cancer patients can be reversed using PD-1-blocking antibodies or DARPin proteins 
856 4 0 |u https://doi.org/10.1155/2020/7375947  |x Verlag  |x Resolving-System  |z lizenzpflichtig  |3 Volltext 
856 4 0 |u https://www.hindawi.com/journals/jir/2020/7375947/  |x Verlag  |z lizenzpflichtig  |3 Volltext 
951 |a AR 
992 |a 20200929 
993 |a Article 
994 |a 2020 
998 |g 1057039187  |a Derani, Judith  |m 1057039187:Derani, Judith  |d 910000  |e 910000PD1057039187  |k 0/910000/  |p 4 
999 |a KXP-PPN1733889515  |e 3763763341 
BIB |a Y 
SER |a journal 
JSO |a {"origin":[{"dateIssuedDisp":"4 August 2020","dateIssuedKey":"2020"}],"id":{"doi":["10.1155/2020/7375947"],"eki":["1733889515"]},"name":{"displayForm":["Emelie Foord, Charlotte Klynning, Esther Schoutrop, Judith M. Förster, Jennifer Krieg, Anette Mörtberg, Mischa R. Müller, Christel Herzog, Dieter Schiegg, Denis Villemagne, Ulrike Fiedler, Dan Snell, Benjamin Kebble, Jonas Mattsson, Victor Levitsky, and Michael Uhlin"]},"physDesc":[{"noteIll":"Illustrationen","extent":"12 S."}],"relHost":[{"title":[{"title":"Journal of immunology research","title_sort":"Journal of immunology research"}],"pubHistory":["Volume 2014-"],"part":{"extent":"12","text":"(2020) Artikel-Nummer 7375947, 12 Seiten","year":"2020"},"type":{"bibl":"periodical","media":"Online-Ressource"},"disp":"Profound functional suppression of tumor-infiltrating T-cells in ovarian cancer patients can be reversed using PD-1-blocking antibodies or DARPin proteinsJournal of immunology research","note":["Gesehen am 04.04.2025"],"recId":"821910469","language":["eng"],"origin":[{"dateIssuedKey":"2024","publisher":"Wiley ; Hindawi","dateIssuedDisp":"2024-","publisherPlace":"[Hoboken, NJ] ; New York, NY"}],"id":{"issn":["2314-7156"],"zdb":["2817541-4"],"eki":["821910469"]},"physDesc":[{"extent":"Online-Ressource"}]}],"title":[{"title":"Profound functional suppression of tumor-infiltrating T-cells in ovarian cancer patients can be reversed using PD-1-blocking antibodies or DARPin proteins","title_sort":"Profound functional suppression of tumor-infiltrating T-cells in ovarian cancer patients can be reversed using PD-1-blocking antibodies or DARPin proteins"}],"person":[{"given":"Emelie","family":"Foord","role":"aut","roleDisplay":"VerfasserIn","display":"Foord, Emelie"},{"role":"aut","display":"Klynning, Charlotte","roleDisplay":"VerfasserIn","given":"Charlotte","family":"Klynning"},{"given":"Esther","family":"Schoutrop","role":"aut","roleDisplay":"VerfasserIn","display":"Schoutrop, Esther"},{"family":"Derani","given":"Judith","display":"Derani, Judith","roleDisplay":"VerfasserIn","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Krieg, Jennifer","given":"Jennifer","family":"Krieg"},{"display":"Mörtberg, Anette","roleDisplay":"VerfasserIn","role":"aut","family":"Mörtberg","given":"Anette"},{"given":"Mischa R.","family":"Müller","role":"aut","display":"Müller, Mischa R.","roleDisplay":"VerfasserIn"},{"family":"Herzog","given":"Christel","roleDisplay":"VerfasserIn","display":"Herzog, Christel","role":"aut"},{"role":"aut","display":"Schiegg, Dieter","roleDisplay":"VerfasserIn","given":"Dieter","family":"Schiegg"},{"display":"Villemagne, Denis","roleDisplay":"VerfasserIn","role":"aut","family":"Villemagne","given":"Denis"},{"family":"Fiedler","given":"Ulrike","roleDisplay":"VerfasserIn","display":"Fiedler, Ulrike","role":"aut"},{"role":"aut","roleDisplay":"VerfasserIn","display":"Snell, Dan","given":"Dan","family":"Snell"},{"given":"Benjamin","family":"Kebble","role":"aut","display":"Kebble, Benjamin","roleDisplay":"VerfasserIn"},{"display":"Mattsson, Jonas","roleDisplay":"VerfasserIn","role":"aut","family":"Mattsson","given":"Jonas"},{"family":"Levitsky","given":"Victor","roleDisplay":"VerfasserIn","display":"Levitsky, Victor","role":"aut"},{"given":"Michael","family":"Uhlin","role":"aut","display":"Uhlin, Michael","roleDisplay":"VerfasserIn"}],"note":["Gesehen am 29.09.2020"],"type":{"media":"Online-Ressource","bibl":"article-journal"},"recId":"1733889515","language":["eng"]} 
SRT |a FOORDEMELIPROFOUNDFU4202